Zevra Therapeutics (ZVRA) Change in Receivables (2019 - 2026)

Zevra Therapeutics (ZVRA) has 8 years of Change in Receivables data on file, last reported at -$6.9 million in Q1 2026.

• Quarterly Change in Receivables fell 426.85% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (down 30.91% YoY) and the FY2025 annual result came in at $12.0 million, up 274.39% from the prior year.
• Change in Receivables eased to -$6.9 million in Q1 2026, from $6.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $7.4 million in Q4 2023 to a low of -$9.1 million in Q1 2024.
• A 5-year average of $827588.2 and a median of $1.8 million in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 2436.26% — and 2024, when it sank 1801.89%.
• Tracing ZVRA's Change in Receivables over 5 years: stood at $2.1 million in 2022, then soared by 250.42% to $7.4 million in 2023, then slumped by 63.5% to $2.7 million in 2024, then surged by 134.17% to $6.4 million in 2025, then tumbled by 208.21% to -$6.9 million in 2026.
• The last three Change in Receivables figures came in at -$6.9 million (Q1 2026), $6.4 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.